Exelixis (EXEL) to Release Quarterly Earnings on Tuesday

Exelixis (NASDAQ:EXEL) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, April 30th. Analysts expect the company to announce earnings of $0.28 per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, February 6th. The biotechnology company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.02. The firm had revenue of $479.65 million for the quarter, compared to analysts’ expectations of $481.23 million. Exelixis had a net margin of 11.35% and a return on equity of 8.57%. On average, analysts expect Exelixis to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Exelixis Stock Up 0.7 %

Exelixis stock opened at $23.70 on Monday. The stock has a market cap of $6.99 billion, a P/E ratio of 37.03, a P/E/G ratio of 0.61 and a beta of 0.54. Exelixis has a twelve month low of $18.08 and a twelve month high of $24.34. The company’s 50-day moving average price is $22.80 and its two-hundred day moving average price is $22.19.

Insider Activity

In other news, Director Alan M. Garber sold 19,205 shares of the firm’s stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $24.01, for a total transaction of $461,112.05. Following the completion of the transaction, the director now owns 35,703 shares of the company’s stock, valued at $857,229.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Exelixis news, Director David Edward Johnson purchased 190,000 shares of the company’s stock in a transaction dated Wednesday, February 21st. The stock was purchased at an average price of $20.70 per share, with a total value of $3,933,000.00. Following the completion of the purchase, the director now owns 1,100,730 shares of the company’s stock, valued at $22,785,111. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Alan M. Garber sold 19,205 shares of Exelixis stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $24.01, for a total transaction of $461,112.05. Following the transaction, the director now directly owns 35,703 shares of the company’s stock, valued at approximately $857,229.03. The disclosure for this sale can be found here. Insiders own 2.90% of the company’s stock.

Analysts Set New Price Targets

EXEL has been the topic of several research analyst reports. JMP Securities reissued a “market outperform” rating and issued a $27.00 price target on shares of Exelixis in a report on Wednesday, April 10th. TheStreet upgraded shares of Exelixis from a “c+” rating to a “b-” rating in a research report on Monday, March 18th. Stifel Nicolaus increased their target price on shares of Exelixis from $23.00 to $25.00 and gave the stock a “hold” rating in a research report on Friday, February 2nd. Royal Bank of Canada increased their target price on shares of Exelixis from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Finally, William Blair restated an “outperform” rating on shares of Exelixis in a research report on Friday, January 26th. Six analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $26.29.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.